References
- CPMP: Note for Guidance on the Investigation of Bioavailability and Bioequivalence. July 2001. Available at: www.emea.europa.eu/pdfs/human/qwp/140198enfin.pdf
- FDA. Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations. March 2003. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf [Last accessed 13 October 2009]
- Eon Labs. Study report number ANA-97-132 submitted by Eon Labs Manufacturing Inc., Laurelton, NY (USA) to the Illinois (USA) Department of Health
- British National Formulary No.55. London: BMJ Group and RPS Publishing, 2008
- Health and Social Care Board. Items unsuitable for generic prescribing 2009: Available at: www.dhsspsni.gov.uk/generic_exception_list_-_regional_aug_09__final_.pdf [Last accessed 13 October 2009]
- Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy. Case evidence of breakthrough seizures. Neurology 2008;71:525-30
- Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease. A systematic review and meta-analysis. JAMA 2008;300:2514-26
- Raw AS, Furness MS, Gill DS, et al. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). Adv Drug Deliv Rev 2004;56:397-414
- Tayrouz Y, Ding R, Burhenne J, et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin Pharmacol Ther 2003;73:397-405
- Wandel C, Kim RB, Stein CM. “Inactive” excipients such as Cremophor can affect in vivo drug disposition. Clin Pharm Ther 2003;73:394-6
- Kovarik JM, Noe A, Wang Y, et al. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. Eur J Clin Pharmacol 2006;62:361-6
- Gomez Y, Adams E, Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand. J Pharm Biomed Anal 2004;34:341-8
- FDA. Review of Therapeutic Equivalence Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg. April 2008. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm153270.htm. [Last accessed 13 October 2009]
- Hellström J, Rudholm N. Side effects of generic competition?. Eur J Health Econom 2004;5:203-8
- Reiffel JA, Kowey PR. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol 2000;85:1151-3
- Epilepsy Action. Anti-epileptic medication packaging survey. Available at: http://www.epilepsy.org.uk/campaigns/survey/aedpackaging. [Last accessed 13 October 2009]
- Burkhardt RT, Leppik IE, Blesi K, et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004;63:1494-6
- Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Arch Intern Med 1988;148:806-8
- MHRA: Drug Safety Update 2009;2(6). Available at: http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON035989 [Last accessed 13 October 2009]
- Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007;9:58
- ACOG. ACOG Issues New Opinion on Brand vs. Generic Oral Contraceptives. August 2007. Available at: www.acog.org/from_home/publications/press_releases/nr08-01-07-1.cfm. [Last accessed 13 October 2009]
- Gerbino PP, Joseph AS. Multisource drugs: implications and concerns in the geriatric population. Hosp Pharm 1993;28:96-98,101-2
- Treur M, Heeg B, Möller HJ, et al. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res 2009;9:32
- Van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23:2101-7
- Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class. Can J Cardiol 2002;18:649-56
- Ringe JD, Möller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis:1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;May 9 [Epub ahead of print]
- Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243-9
- Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
- Switching statins. Bandolier 157 2007;14(3):1-8
- Phillips B, Roberts C, Rudolph AE, et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-5
- Wiviott SD, Braunwald E, McCabe CH, et al for the TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007;357:2001-15
- Pedersen TR, Faergeman P, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled Trial. JAMA 2005;294:2437-45
- Harris International. Consumers’ views on therapeutic substitution. September 2008. Available at: http://www.nclnet.org/health/therapeutic_substitution.pdf. [Last accessed 13 October 2009]
- Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference pricing for angiotensin-converting enzyme inhibitors. N Engl J Med 2002;346:822-9
- Dahlöf B, Sever PS, Poulter NR, et al. for the ASCOT investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
- Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671-81
- Marentette MA, Gerth WC, Billings, DK, et al. Antihypertensive Persistence and drug class. Can J Cardiol 2002;18:649-56
- Pylypchuk GB. ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-6
- Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety 2005;28:601-31
- Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
- Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160:41-6
- Schroeder SA, Cantor JC. On squeezing balloons. Cost control fails again. N Engl J Med 1991;325:1099-100
- National Institute of Health. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. NIH, 2003
- Kjoenniksen I, Lindbaek M, Granas A. Patients’ attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006;28:284-9
- Dowell JS, Snadden D, Dunbar JA. Changing to generic formulary: how one fundholding practice reduced prescribing costs. BMJ 1995;310:505-8
- Dealing with the downturn: the greatest ever leadership challenge for the NHS? Available at: http://www.nhsconfed.org/Publications/Documents/Dealing_with_the_downturn.pdf. [Last accessed 13 October 2009]
- BMA response. A review of the consequences of additional private drugs for NHS care. Led by Professor Mike Richards on behalf of the Secretary of State for Health. Available at: http://www.bma.org.uk/images/RichardsReview_tcm41-178745.pdf. [Last accessed 13 October 2009]
- Council of Europe Health Policy. Available at: http://www.coe.int/t/dg3/health/recommendations_en.asp#policy. [Last accessed 13 October 2009]
- WHO Rational Use of Medicines: Activities. Available at: http://www.who.int/medicines/areas/rational_use/rud_activities/en/index.html. [Last accessed 13 October 2009]
- The European Directorate for the Quality of Medicines and healthcare (EDQM). Available at: http://www.edqm.eu/site/Pharmaceuticals_Pharmaceutical_care-1271.html. [Last accessed 13 October 2009]
- Figueras J, McKee M, Lessof S, et al. Health systems, health and wealth: Assessing the case for investing in health systems. World Health Organization 2008 and World Health Organization, on behalf of the European Observatory on Health Systems and Policies 2008. Available at: http://www.euro.who.int/document/hsm/3_hsc08_eBD3.pdf. [Last accessed 13 October 2009]
- The European Federation of Pharmaceutical Industries and Associations (EFPIA): Position Paper. Use of HTAs to evaluate medicines (July 2005). Available at: http://212.3.246.100/Objects/2/Files/HTAprinciplesEFPIApositionpaperFinal.pdf. [Last accessed 13 October 2009]
- The Pharmaceutical Price Regulation Scheme (PPRS). Available at: www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH_091825. [Last accessed 13 October 2009]